EP2 agonists

Details EP2 agonists EP2 agonists

2007-07-27

2009-11-24

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S255000, C548S125000

Reexamination Certificate

active

07622475

ABSTRACT:
The invention provides EP2 agonists, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for lowering intraocular pressure and thereby treating glaucoma.

REFERENCES:
patent: 4599353 (1986-07-01), Bito
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 6288120 (2001-09-01), Cameron et al.
patent: 6344485 (2002-02-01), Cameron et al.
patent: 6492412 (2002-12-01), Cameron et al.
patent: 6498172 (2002-12-01), Cameron et al.
patent: 6649657 (2003-11-01), Cameron et al.
patent: 2002/0115695 (2002-08-01), Paralkar
patent: 2002/0161026 (2002-10-01), Paralkar
patent: 2003/0166631 (2003-09-01), Dumont et al.
patent: 2004/0176423 (2004-09-01), Paralkar
patent: 2005/0203086 (2005-09-01), Constan et al.
patent: 1 000 619(A2) (2000-05-01), None
patent: 1 108 426(A2) (2001-06-01), None
patent: 1 205 189(A2) (2002-05-01), None
patent: 1 108 426(A3) (2002-10-01), None
patent: WO 98/28264 (1998-07-01), None
patent: WO 99/19300 (1999-04-01), None
patent: WO 9919300 (1999-04-01), None
patent: WO 03/045371(A1) (2003-06-01), None
patent: WO 2004/078169 (2004-09-01), None
Vippagunta et al., “Crystalline solids”, Adv. Drug Delivery Reviews 48 (2001) 3-26.
Anand, B.S., et al., “Current Prodrug Strategies Via Membrane Transporters/Receptors,”Expert Opinion on Biological Therapy, 2002, 607-20, vol. 2, No. 6.
Beaumont, K., et al., “Design Of Ester Prodrugs To Enhance Oral Absorption of Poorly Permeable Compounds: Challenges To The Discovery Scientist,”Current Drug Metabolism, 2003, 461-85, vol. 4, No. 6.
Ettmayer, G.L., et al., “Lessons Learned From Marketed And Investigational Prodrugs,”J. Med. Chem., 2004, 2393-2404, vol. 47, No. 10.
Flatch, A., et al., “Topical Prostaglandin E2Effects on Normal Human Intraocular Pressure”,Journal of Ocular Pharmacology, 1988, 13-18, vol. 4, No. 1.
Papot, S., et al., “Design of Selectively Activated Anticancer Prodrugs: Elimination And Cyclization Strategies,”Current Medicinal Chemistry—Anti-Cancer Agents, 2002, 155-85, vol. 2 No. 2.
Schultz, C., “Prodrugs of Biologically Active Phosphate Esters,”Bioorganic And Medicinal Chemistry, 2003, 885-98, vol. 1, No. 6.
Smyth, T.P., et al., “Beta-Lactamase-Dependent Prodrugs—Recent Developments,”Tetrahedron, 2000, 5699-5707, vol. 56, No. 31.
Stella, V. J., “Prodrugs As Therapeutics, Expert Opinion On Therapeutic Patents,” 2004, 277-280, vol. 14, No. 3.
Testa, B., “Prodrug Research: Futile or Fertile?,”Biochemical Pharmacology, 2004, 2097-2106, vol. 68, No. 11.
Testa, B., et al., “Design Of Intramolecularly Activated Prodrugs,”Drug Metabolism Review, 1998, 787-807, vol. 30, No. 4.
Tsvetkova, B.P., et al., “Prodrugs And Hydrolysis Of Esters,”Pharmacia, 2001, 45-57, vol. 48 Nos. 1-4.
Woodward, D.F., et al., “Molecular Characterization and Ocular Hypotensive Properties of the Prostanoid EP2Receptor,”Journal of Ocular Pharmacology and Therapeutics, 1995, 447-454, vol. 11, No. 3.

Affiliated with

Also associated with

Rating

EP2 agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EP2 agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EP2 agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4071298